Dr. Aguilar-Cordova is a recognized leader in the fields of biotherapeutics and cancer research with over 25 years experience in Molecular Biology and
Medicine, GMP biological manufacturing and as principal or co-investigator in over twenty clinical trials ranging from Phase I-III.
Prior to moving into his current role as CEO Advantagene, a privately held clinical –stage biotechnology company, he held academic faculty
positions for over 15 years. Most recently he was Deputy Director of the Harvard Gene Therapy Initiative at the Harvard Medical School
and prior to that a faculty member in Pediatrics, Hematology-Oncology at Baylor College of Medicine. He has served in many national
oversight committees, including as chair and member of the NIH Recombinant Advisory Committee (RAC) for six years, as a consultant to the
FDA Biological Response Modifiers Advisory Committee (BRMAC) and as a member of the Vaccine and Related Products Advisory Committee (VRPAC)
of the FDA. He has held many other prestigious appointments including Director of Cell and Molecular Therapy Laboratories at the Texas
Children’s Hospital in Baylor College of Medicine, Houston, TX and President of the Latin American Gene Therapy Society. Dr. Aguilar-Cordova
has published over 75 peer-reviewed scientific publications and book chapters, is on the editorial board of various professional journals
and is an inventor on several patent applications. He did his undergraduate studies in Biology at California State University,
Bakersfield; Medicine, at Universidad Francisco Marroquin in Guatemala City, and received his Ph.D. in Molecular Genetics
at the University of California at Davis.